title: Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder.
abstract: The so-called atypical forms of bipolar disorder are not a rarity, but instead are rather the rule. Particularly in specialized settings such as the bipolar disorder clinic, the majority of patients are characterized by atypical manifestations (). Mixed states, psychotic mania and a rapid cycling course of bipolar disorder are a challenge both to pharmacological and non-pharmacological treatment. The benefit of classical mood stabilizers such as lithium and carbamazepine is limited in monotherapy, although valproate has a broader spectrum of activity in atypical bipolar disorders and is often used in combination with other agents. Thus, new treatment alternatives are needed urgently for optimizing the treatment of atypical bipolar disorder. During the last decade, several new antiepileptic drugs have been released, e.g. lamotrigine, gabapentin, tiagabine, topiramate and levetiracetam. Others have been available for some time, but only recently have become the focus of bipolar disorder research; for example, phenytoin, and especially, oxcarbazepine. This review will consider our current knowledge of the benefit of these new and newly rediscovered anticonvulsants in treating bipolar disorders, with a special focus on their value in treating atypical manifestations.
authors.affiliation: Department of Psychiatry, LMU, Nussbaumstr. 7, D-80336 Munich, Germany. grunze@psy.med.uni-muenchen.de
authors.forename: Heinz
authors.initials: H
authors.lastname: Grunze
authors.forename: Jörg
authors.initials: J
authors.lastname: Walden
mesh_terms: D000339:Affect / Q000187:drug effects; D000927:Anticonvulsants / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology*; D002986:Clinical Trials as Topic; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants